Biochips as Pathways to Drug Discovery (Drug Discovery Series Book 7)

In the fiercely competitive pharmaceutical marketplace, your organization cannot afford to spend excess dollars developing drugs that will fail to get FDA approval or have profoundly poor characteristics. Biochips as Pathways to Drug Discovery takes a comprehensive look at how the industry faces these challenges, using new technologies such as biochips to reduce the cost of drug discovery and improve drug safety. The book explores the tools and skills required at each step of the discovery process when using biochips to determine biological outcomes. The authors provide an in-depth review of the clinical and pharmacogenomic relevance of biochips, ChIP-chip assays, and high-throughput approaches. They discuss how biochips are used to develop biomarkers in the drug discovery process, primarily for gene expression profiling and Single Nucleotide Polymorphism (SNP) analysis. The book includes coverage of experimental theory, quality control, clinical laboratory sampling considerations, database concepts, industrial laboratory design, and the analysis of the resultant large data sets. It discusses the application of biochips to the study of malaria, toxicogenomics, and SNPs, as well as intellectual property and market overviews. The book concludes with a comprehensive overview of how these chips are employed from early target discovery through preclinical toxicology and on through to pharmacogenomic and proof of concept studies in humans. Written in an easily accessible style, the breadth of coverage introduces the subject to those new to the field, while the depth of coverage forms a foundation for future work. The book gives you the knowledge required to leverage the technology into bona fide discoveries. Daniel E. Levy, editor of the Drug Discovery Series, is the founder of DEL BioPharma, a consulting service for drug discovery programs. He also maintains a blog that explores organic chemistry.

in The Fiercely Competitive Pharmaceutical Marketplace, Your Organization Cannot Afford To Spend Excess Dollars Developing Drugs That Will Fail To Get Fda Approval Or Have Profoundly Poor Characteristics. biochips As Pathways To Drug Discovery Takes A Comprehensive Look At How The Industry Faces These Challenges, Using New Technologies Such As Biochips To Reduce The Cost Of Drug Discovery And Improve Drug Safety. The Book Explores The Tools And Skills Required At Each Step Of The Discovery Process When Using Biochips To Determine Biological Outcomes.

the Authors Provide An In-depth Review Of The Clinical And Pharmacogenomic Relevance Of Biochips, Chip-chip Assays, And High-throughput Approaches. They Discuss How Biochips Are Used To Develop Biomarkers In The Drug Discovery Process, Primarily For Gene Expression Profiling And Single Nucleotide Polymorphism (snp) Analysis. The Book Includes Coverage Of Experimental Theory, Quality Control, Clinical Laboratory Sampling Considerations, Database Concepts, Industrial Laboratory Design, And The Analysis Of The Resultant Large Data Sets. It Discusses The Application Of Biochips To The Study Of Malaria, Toxicogenomics, And Snps, As Well As Intellectual Property And Market Overviews. The Book Concludes With A Comprehensive Overview Of How These Chips Are Employed From Early Target Discovery Through Preclinical Toxicology And On Through To Pharmacogenomic And Proof Of Concept Studies In Humans.

written In An Easily Accessible Style, The Breadth Of Coverage Introduces The Subject To Those New To The Field, While The Depth Of Coverage Forms A Foundation For Future Work. The Book Gives You The Knowledge Required To Leverage The Technology Into Bona Fide Discoveries.

Front cover; Preface; Acknowledgments; The Editors; Contributors; Table of Contents; Chapter 1. DNA Biochips Past, Present, and Future: An Overview; Chapter 2. Three-Dimensional HydroArrays: Novel Microarrays for Genomic and Proteomic Studies; Chapter 3. Biochips in Malaria for Antiparasitic Discovery; Chapter 4. Regional Variations in Intestinal ATP-Binding Cassette Transporter Expression Identified with a Global Error Assessment Model*; Chapter 5. Toxicogenomics in Drug Safety Evaluation: Bridging Drug Discovery and Development. Chapter 6. The Next Generation of Automated Microarray Platforms for a Multiplexed CYP2D6 AssayChapter 7. Evaluation of Skeletal Muscle and Adipose Tissue Biopsy Procedures for Microarray-Based Gene-Expression Profiling; Chapter 8. ChIP-on-Chip: Analysis of Genomewide Protein Binding and Posttranslational Modifications; Chapter 9. DNA Microarrays as Functional Genomics Tools for Cancer Drug Discovery; Chapter 10. High-Throughput Microarray Analysis; Chapter 11. La. The DNA microarray field is expected to thrive in coming years, driving new discoveries and expanding into many new breakthrough areas. The coupling of informatics and automation to this field with profound applications to drug discovery is explored in detail. Biochips as Pathways to Drug Discovery provides a comprehensive and real world examination of biochip technologies and their applications to drug discovery for the student, scientist or investor. This forward-thinking book provides a comprehensive overview of the current state of biochip technology, examining the effects of biochips on biomedical research and specifically the pharmaceutical industry. It presents technology platforms in detail and explores the clinical relevance of biochips, Chip-chip assays, and high-throughput approaches The DNA microarray field is expected to thrive in the coming years, expanding into areas of robotics, nucleic acid chemistries, and informatics. With perspectives that look ahead to the future of this area, ''Biochips as Pathways to Drug Discovery'' provides a comprehensive overview of the current state of biochip technology, examining the effects of biochips on biomedical research and specifically the pharmaceutical industry. This text presents technology platforms in detail and explores the clinical relevance of biochips, Chip-chip assays, and high-throughput approaches in depth. It also cov. Explores the tools and skills required at each step of the discovery process when using biochips to determine biological outcomes. This work provides a review of the clinical and pharmacogenomic relevance of biochips, ChIP-chip assays, and high-throughput approaches.